Altium Capital Management’s Travere Therapeutics TVTX Stock Holding History

Altium Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-141,000	Closed	-$4.38M	–	153
2021 Q4	$4.38M	Hold	141,000	–	–	1.21%	32
2021 Q3	$3.42M	Sell	141,000 -29,484	-17%	-$542K	0.9%	48
2021 Q2	$2.49M	Sell	170,484 -40,000	-19%	-$789K	0.58%	71
2021 Q1	$5.26M	Buy	210,484 +134,000	+175%	+$3.7M	1.46%	20
2020 Q4	$2.08M	Buy	+76,484	New	+$1.79M	0.78%	55

Other funds holding TVTX

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Altium Capital Management's TVTX Position: Q1 2022 in Review

Altium Capital Management sold out of Travere Therapeutics (TVTX) in Q1 2022, closing a stake of 141,000 shares — an estimated $4.38M sold.

Altium Capital Management first reported a position in TVTX in Q4 2020 and held it in 5 quarters. The position peaked at $5.26M in Q1 2021. 169 funds tracked by Wall St. Rank hold TVTX as of Q1 2022.

Altium Capital Management reported no remaining Travere Therapeutics position as of Q1 2022 after selling out during the quarter.
Altium Capital Management sold 141,000 Travere Therapeutics shares in Q1 2022, an estimated $4.38M.
Altium Capital Management first reported a position in Travere Therapeutics in Q4 2020 and held it in 5 quarters.
Altium Capital Management's Travere Therapeutics position peaked at $5.26M in Q1 2021.
169 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2022.

Based on Altium Capital Management's 13F filing for Q1 2022, filed 16 May 2022.